Table 2

Prevalence of Myonecrosis and Secondary End Points

Aspirin ResistantAspirin Sensitivep ValueClopidogrel Low ResponderClopidogrel Responderp Value
Myonecrosis11.1% (1/9)27.8% (49/176)0.25923.5% (12/51)29.3% (43/147)0.433
CK-MB >3× ULN11.1% (1/9)2.3% (4/176)0.1123.9% (2/51)2.1% (3/146)0.467
REPLACE-2 major bleeding0.0% (0/9)2.3% (4/176)0.6483.9% (2/51)2.7% (4/147)0.667
REPLACE-2 minor bleeding22.2% (2/9)22.2% (39/176)0.99617.6% (9/51)29.3% (43/147)0.125
30-day death, MI, urgent TVR11.1% (1/9)2.3% (4/176)0.1122.0% (1/51)2.7% (4/147)0.766

CK-MB = creatine kinase-myocardial band; MI = myocardial infarction; REPLACE = Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events; TVR = target vessel revascularization; ULN = upper limit of normal.